Propanc Biopharma board member departs, accountant Carlo Campiciano appointed to replace her

Propanc Biopharma, Inc. disclosed in an 8-K that effective July 8, 2026, Annie Van Broekhoven retired and stepped down from the Board of Directors of Propanc Biopharma, Inc., and the company accepted her resignation.¹ That same day, the board filled the vacancy left by Ms. Van Broekhoven's resignation by appointing Carlo Campiciano to serve on the board until his resignation or removal.¹

According to the filing, Campiciano is a qualified accountant and a member of the Institute of Public Accountants in Australia, with a background in taxation, finance operations, planning and financial strategy.¹ His academic credentials include a Master of Entrepreneurship and Innovation from Swinburne University of Technology, a Graduate Diploma in Computing from Monash University Caulfield (formerly Caulfield Institute of Technology), a Bachelor of Business (Accounting) from RMIT University, and a Certificate in Corporate Governance from the Governance Institute.¹ He also holds US GAAP certification.¹

The filing states that Campiciano has been the CFO and Company Secretary of MedAdvisor Limited, a company listed on the Australian Securities Exchange (ASX).¹ It notes he was on the founding team that started MedAdvisor in 2012, and has helped raise multiple funding rounds and worked on the company's ASX listing in December 2015.¹ The document further says he played a role in MedAdvisor's strategic and operational growth, including its expansion into a market-leading position in Australia and its establishment of operations in the United States and Asia.¹ Separately, he taught venture finance for twelve years as part of the Masters of Entrepreneurship and Innovation program at Swinburne's Graduate School of Entrepreneurship.¹

The filing includes a Director Agreement dated July 8, 2026 between Propanc Biopharma, Inc. and Carlo Campiciano¹ as an exhibit. The 8-K was signed by CEO and CFO James Nathanielsz and dated July 14, 2026.